Ceretype Neuromedicine
Cambridge, United States · Biotechnology · 7 employees
Ceretype has pioneered the integration of fMRI into therapeutic applications in neuropsychiatry. Our uniquely scalable platform makes targeted biomarkers accessible, delivering actionable insights for our pharma/biotech partners. Our decades of expertise across neuromedicine, brain imaging, and industry processes enables innovations that will ultimately transform patient care.
Funding history
- Series seed — $400K — Dec 2025
- Series seed — Undisclosed — Jan 2024
- Series seed — $1.4M — Nov 2021
Recent signals
- Dec 18, 2025: Raised $400K in Series seed
- Jan 04, 2024: Raised funding in Series seed
- Nov 22, 2021: Raised $1.4M in Series seed
See plans & pricing → Track Ceretype Neuromedicine’s funding, hiring, and signals — with verified contacts — on Fundz.